FY 2025 (No.418-)
Issue |
No. |
Table of contents |
April 2025 |
418 |
Full text [684 KB]
- Article 1. Efforts Against Abuse of Over-the-Counter Drugs
- Article 2. Important Safety Information
Article 2.-1 Dulaglutide (genetical recombination)
- Article 3. Revisions of PRECAUTIONS (No.358)
Article 3.-1 Dulaglutide (genetical recombination) (and 4 others)
- Article 4. List of Products Subject to Early Post-marketing Phase Vigilance
|